BioPharma

For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients. Source: BioSpace

Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning. Source: BioSpace

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading. Source: BioSpace

Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC). Source: BioSpace

Allecra Therapeutics released positive top-line data from its Phase II trial of AAI101, an antibiotic against gram-negative bacteria. Source: BioSpace

GlaxoSmithKline has decided not to make a play for Pfizer’s consumer health business. The decision came one day after another potential suitor walked away from a potential deal. Source: BioSpace

Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering. Source: BioSpace

Healthcare companies are now looking at pharma executives for leadership roles as the landscape of healthcare is dramatically changing. Source: BioSpace

MorphoSys, a Germany-based biopharmaceutical company, is aiming for a listing on the Nasdaq exchange hoping to secure approximately $150 million. Source: BioSpace

After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug. Source: BioSpace